HDFC Mid Cap Fund
The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies.
Growthvine rating: 5/5 — ranked #1 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹195.10 (as of 2026-10-22) |
|---|
| AUM | ₹1,01,856 Cr |
|---|
| Expense ratio | 1.09% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Chirag Setalvad |
|---|
| Exit load | 1% for redemption within 365 days |
|---|
Performance & risk
| 5-year annualised return | 16.74% |
|---|
| Sharpe ratio | 0.58 |
|---|
| Standard deviation | 16.12% |
|---|
| Max drawdown | −60.80% |
|---|
| Alpha | 2.57 |
|---|
| Beta | 0.86 |
|---|
Over 5 years, captured 93.6% of NIFTY Midcap 150's upside and 78.3% of its downside.
Market cap allocation
| Large cap | 11.3% |
|---|
| Mid cap | 69.9% |
|---|
| Small cap | 18.8% |
|---|
Concentration
| Top 5 holdings | 17.9% |
|---|
| Top 10 holdings | 31.3% |
|---|
| Total holdings | 79 |
|---|
| Index overlap | 30.2% |
|---|
| Active share | 69.8% |
|---|
Top holdings
- TREPS - Tri-party Repo — 8.4%
- Federal Bank Ltd. — 4.0%
- AU Small Finance Bank Limited — 3.9%
- Max Financial Services Limited — 3.5%
- Ipca Laboratories Ltd. — 3.4%
- Glenmark Pharmaceuticals ltd — 3.1%
- Balkrishna Industries Ltd. — 3.0%
- Indian Bank — 2.9%
- COFORGE LIMITED — 2.7%
- Fortis Healthcare Ltd — 2.4%
Top sectors
- Banking & Financial — 16.6%
- Pharma & Biotech — 12.1%
- Automobile — 9.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −4.1% | Q3 | #22 of 31 |
| 2025 | 6.8% | Q1 (Top) | #3 of 29 |
| 2024 | 28.6% | Q2 | #15 of 29 |
| 2023 | 44.5% | Q1 (Top) | #4 of 28 |
| 2022 | 12.3% | Q1 (Top) | #2 of 22 |